In a surprise bid to bolster its fortunes, GlaxoSmithKline (GSK) agreed to pay $5.1 billion for Tesaro (TSRO), which sells a so-called PARP inhibitor in the burgeoning but highly competitive oncology market. These medicines have increased survival rates for women with recurrent ovarian cancer, and are also exhibiting promise for treating other forms of cancer, such as lung, breast and prostate.

Glaxo chief executive Emma Walmsley called Zejula a “jewel in the PARP class” and heralded the purchase as a “significant development” in her efforts to refocus the drug maker, a move that last year included hiring former Genentech R&D chief Hal Barron. For his part, Barron argued “there is an enormous amount of science that is evolving and this is just the tip of the iceberg.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy